2min chapter

Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

CHAPTER

E-Petroboryl, A&2 Therapeutics

E-petroboryl, A&2 Therapeutics is a bioformaceutical company that actually uses a boron chemistry platform. This compound has a novel mechanism of action where an enzyme involved in protein synthesis called lucil tRNA synthetase is actually locked together to the terminal adenosine ribose of tRNA. In terms of in vitro activity, it has MICs demonstrated between 0.25 and 8. It has also excitingly demonstrated activity against chlorothermysin and ama casein resistant isolates.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode